ABL Bio Inc (298380) - Cash Flow Conversion Efficiency

Latest as of December 2025: -0.151x

Based on the latest financial reports, ABL Bio Inc (298380) has a cash flow conversion efficiency ratio of -0.151x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩-23.62 Billion ≈ $-16.01 Million USD) by net assets (₩156.70 Billion ≈ $106.19 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

ABL Bio Inc - Cash Flow Conversion Efficiency Trend (2016–2025)

This chart illustrates how ABL Bio Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read ABL Bio Inc (298380) financial obligations for a breakdown of total debt and financial obligations.

ABL Bio Inc Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of ABL Bio Inc ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
Subsea 7 S.A F:SOCA	0.066x
Jiangsu Boqian New Materials Stock Co Ltd SHG:605376	0.031x
ExlService Holdings Inc NASDAQ:EXLS	0.127x
Enstar Group Limited NASDAQ:ESGR	0.023x
Compagnie Generale des Etablissements Michelin SCA LSE:0OFM	0.069x
TDG Holding Co Ltd SHG:600330	0.001x
Petronas Dagangan Bhd KLSE:5681	0.076x
ASM Pacific Technology Limited F:AY7A	N/A

Annual Cash Flow Conversion Efficiency for ABL Bio Inc (2016–2025)

The table below shows the annual cash flow conversion efficiency of ABL Bio Inc from 2016 to 2025. For the full company profile with market capitalisation and key ratios, see market cap of ABL Bio Inc.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-12-31	₩156.70 Billion ≈ $106.19 Million	₩-41.25 Billion ≈ $-27.96 Million	-0.263x	+36.55%
2024-12-31	₩167.28 Billion ≈ $113.36 Million	₩-69.40 Billion ≈ $-47.03 Million	-0.415x	-8.37%
2023-12-31	₩74.08 Billion ≈ $50.20 Million	₩-28.36 Billion ≈ $-19.22 Million	-0.383x	-136.90%
2022-12-31	₩69.51 Billion ≈ $47.11 Million	₩72.13 Billion ≈ $48.88 Million	1.038x	+242.99%
2021-12-31	₩55.95 Billion ≈ $37.92 Million	₩-40.61 Billion ≈ $-27.52 Million	-0.726x	-39.12%
2020-12-31	₩90.66 Billion ≈ $61.44 Million	₩-47.29 Billion ≈ $-32.05 Million	-0.522x	-188.67%
2019-12-31	₩132.01 Billion ≈ $89.46 Million	₩-23.86 Billion ≈ $-16.17 Million	-0.181x	-123.90%
2018-12-31	₩156.96 Billion ≈ $106.37 Million	₩-12.67 Billion ≈ $-8.59 Million	-0.081x	-197.13%
2017-12-31	₩-85.96 Billion ≈ $-58.25 Million	₩-7.14 Billion ≈ $-4.84 Million	0.083x	-67.72%
2016-12-31	₩-12.10 Billion ≈ $-8.20 Million	₩-3.12 Billion ≈ $-2.11 Million	0.257x	--

About ABL Bio Inc

KQ:298380 Korea Biotechnology

Market Cap

$5.04 Billion

₩7.43 Trillion KRW

Market Cap Rank

#3574 Global

#93 in Korea

Share Price

₩134800.00

Change (1 day)

-5.07%

52-Week Range

₩59700.00 - ₩245500.00

All Time High

₩245500.00